Evidence map›Paper›PMID 38740809›Full record

ArticleScientific reports2024

A bicentric retrospective study of the correlation of EAU BCR risk groups with

Nathan Poterszman, Charles Merlin, Charles Margail, Eric Ouvrard, Alessio Imperiale, François Somme

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nathan PoterszmanNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe, 17 Rueueue Albert Calmette, 67000, Strasbourg, France.
Charles MerlinNuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.
Charles MargailNuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.
Eric OuvrardNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe, 17 Rueueue Albert Calmette, 67000, Strasbourg, France.
Alessio ImperialeNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe, 17 Rueueue Albert Calmette, 67000, Strasbourg, France.
François SommeNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe, 17 Rueueue Albert Calmette, 67000, Strasbourg, France. f.somme@icans.eu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Association of Urology (EAU) has proposed a risk stratification for patients harboring biochemical recurrence (BCR) after radical prostatectomy: ISUP < 4 and PSA doubling time (PSAdt) > 12 months for low risk, and ISUP ≥ 4 or PSAdt ≤ 12 months for high risk. This dual-center retrospective study aims to investigate the correlation between the EAU risk stratification for BCR following radical prostatectomy and the detection rate of lesions using

Indexed as

Neoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedHumansMaleMiddle AgedNiacinamideOligopeptidesProstatectomyProstate-Specific AntigenRetrospective StudiesNiacinamideOligopeptidesProstate-Specific AntigenPSMA-1007

Identifiers

PMID38740809
PMCPMC11091042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.